Novartis has announced the launch of Novartis Biome Sub-Saharan Africa, a new innovation hub (SSA). It is the region’s driving force in developing innovative business structures and technical solutions to improve healthcare. The cluster will concentrate on forming intersectoral partnerships in order to expedite new methods to increasing affordable access to high-quality medications and strengthening health systems in the long run.

Read also South African Fintech Firm, Crossfin, Acquired For $94.3m 

Novartis Biome SSA will concentrate on four strategic goals: increasing healthcare accessibility, improving early diagnosis for improved outcomes, leading supply chain innovation, and supporting healthcare professional education and patient awareness. Working on these four initiatives will help Novartis achieve its goal of doubling its patient base in Sub-Saharan Africa by 2022 and tripling it by 2025.

“Our mission is to provide inexpensive access to high-quality medicines to every patient in Sub-Saharan Africa, thereby transforming healthcare in the region. Innovation and digital technologies have enormous potential to contribute to this, and cross-sector cooperation may truly optimize the impact on our population’s health,” Novartis Sub-Saharan Africa President and CEO Racey Muchilwa stated.

Novartis Innovation Hub Africa

Charles Rapulu Udoh

Charles Rapulu Udoh is a Lagos-based lawyer who has advised startups across Africa on issues such as startup funding (Venture Capital, Debt financing, private equity, angel investing etc), taxation, strategies, etc. He also has special focus on the protection of business or brands’ intellectual property rights ( such as trademark, patent or design) across Africa and other foreign jurisdictions.
He is well versed on issues of ESG (sustainability), media and entertainment law, corporate finance and governance.
He is also an award-winning write